Capstan Therapeutics
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases using its proprietary CellSeeker tLNP platform. Its technology deploys targeted lipid nanoparticles conjugated with protein binders—such as antibodies—to reprogram specific cell types within the body, including CAR-T cells, without ex vivo manipulation. The lead candidate, CPTX2309, delivers an anti-CD19 CAR payload to CD8⁺ T cells and aims to reset B cell–driven autoimmune disease, currently in Phase 1 trials.
Domain
capstantx.com
Country
United StatesIndustry
BiotechnologyEmployees
101-250
Last Funding
$175.0M
Founded
2020
Tech Stack (14 technologies)
Frequently Asked Questions
What technologies does Capstan Therapeutics use?+
Capstan Therapeutics uses 14 technologies including Adobe Experience Manager, Google Tag Manager, OneTrust.
What industry is Capstan Therapeutics in?+
Capstan Therapeutics operates in the Biotechnology industry.
Where is Capstan Therapeutics based?+
Capstan Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026